Product recalls, lobbying, and firm value

Abstract

The paper uses a unique, hand-collected data set of Food and Drug Administration (FDA)-approved products to understand the effect of lobbying on the product market. The authors gather total 86,462 FDA labels including drug patents, drugs, pre-market approvals and medical devices and test the relationship between lobbying and future firms’ product submissions.

Publication
Management Decision
Avatar
Blake Rayfield
Associate Professor of Finance

Blake Rayfield, PhD, is an Associate Professor of Finance at Northern Arizona University and a Fulbright Scholar. His research focuses on Financial Technology, Corporate Finance, and Investments.